Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 499 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Reflux Clear all
Withdrawn Not applicable Interventional

HRIM vs Mucosal Impedance in GERD Participants

NCT02812407
View directory record Official record
Conditions
Gastro-esophageal Reflux Disease (GERD)
Interventions
Mucosal Impedance
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?

NCT00444145
View directory record Official record
Conditions
Larynx Disease, Gastroesophageal Reflux
Interventions
Prevacid, Esophageal and Laryngeal Biopsies
Drug · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

NCT05055128
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
X842, X842 Dummy, Lansoprazole, Lansoprazole Dummy
Drug
Lead sponsor
Cinclus Pharma Holding AB
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mechanisms Preventing Pharyngeal Reflux

NCT05696184
View directory record Official record
Conditions
GERD
Interventions
Concurrent manometry/impedance/pH with video pharyngo-laryngoscopy, Slow and rapid intra-esophageal infusion
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Completed No phase listed Observational

Medical and Surgical Treatment of Esophageal Reflux

NCT00061724
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Maywood, Illinois • Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional

A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders

NCT01116388
View directory record Official record
Conditions
Autism, Gastrointestinal Symptoms
Interventions
GFCF product with GFCF diet, product containing gluten and casein (milk protein) with GFCF diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 21, 2026, 4:25 PM EDT
Not listed No phase listed Observational

Serial Exhaled Breath pH Monitoring

NCT00330603
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Serial exhaled breath collections
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
5 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 3 Interventional

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Nexium 20mg, Nexium 10mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Edwards CLASP TR EFS

NCT03745313
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Edwards PASCAL Transcatheter Valve Repair System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 21, 2026, 4:25 PM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Omega Cuff for GERD Feasibility Study

NCT04793035
View directory record Official record
Conditions
GERD, Acid Reflux, Treatment
Interventions
Omega-Cuff
Device
Lead sponsor
Aplos Medical
Industry
Eligibility
22 Years to 74 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Los Angeles, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.

NCT00237068
View directory record Official record
Conditions
Asthma
Interventions
Lansoprazole; Solutab
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 21, 2026, 4:25 PM EDT
Completed No phase listed Observational

Epidemiology of Barrett's Esophagus: A Population Based Study

NCT01286155
View directory record Official record
Conditions
Barrett's Esophagus, Gastroesophageal Reflux Disease (GERD), Olmsted County Resident
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 21, 2026, 4:25 PM EDT
Active, not recruiting Not applicable Interventional

Gracie Diet for Gastroesophageal Reflux Disease

NCT04360252
View directory record Official record
Conditions
Gastroesophageal Reflux, GERD
Interventions
Gracie Diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 21, 2026, 4:25 PM EDT
Recruiting No phase listed Observational

Abbott Cephea Mitral Valve Disease Registry

NCT07069673
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Annulus Calcification, Mitral Valve Replacement, Transcatheter Valve Replacement
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Comparative Anti-Reflux Procedures in Neurologically Impaired Children

NCT01307982
View directory record Official record
Conditions
Gastroesophageal Reflux, Nervous System Diseases, Fundoplication, Enteral Nutrition
Interventions
Fundoplication, Gastrojejunal (GJ) feeding tube
Procedure
Lead sponsor
University of Utah
Other
Eligibility
6 Months to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

NCT01126034
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Diabetic Gastroparesis
Interventions
intervention letter
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

NCT00259012
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole sodium enteric-coated spheroid suspension
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
1 Month to 11 Months
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease

NCT00215787
View directory record Official record
Conditions
Nasal Polyps, Gastroesophageal Reflux
Interventions
lansoprazole
Drug
Lead sponsor
Head and Neck Surgery Associates
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Oct 21, 2026, 4:25 PM EDT
Terminated Phase 2 Interventional Results available

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

NCT01821898
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Budesonide, Elimination diet
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 21, 2026, 4:25 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 21, 2026, 4:25 PM EDT
Completed No phase listed Observational

Upper GI MM vs Manometry

NCT06973070
View directory record Official record
Conditions
GERD (Gastroesophageal Reflux Disease)
Interventions
Not listed
Lead sponsor
Lexington Health Incorporated
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 21, 2026, 4:25 PM EDT